文献速递免疫规划

2010-2012年美国儿童接种减毒活流感疫苗后14天内住院情况分析

Hospitalizations within 14days of vaccination among pediatric recipients of the live attenuated influenza vaccine, United States 2010-2012.
PubMed 文献 · Vaccine · 2016-12-29

基于MarketScan商业索赔数据库2010-2012年数据,分析2-18岁接种减毒活流感疫苗(LAIV)儿童接种后14天内住院情况。采用自控病例系列分析,比较有非哮喘非免疫受损基础病与无基础病儿童的全因住院发生率比。结果显示两组在接种后1-7天和8-14天风险窗口内全因住院风险均无显著差异。

要点

  • 有非哮喘非免疫受损基础病儿童接种LAIV后1-7天全因住院IRR为1.1(95%CI 0.6-2.0,p=0.83)。
  • 无基础病儿童接种LAIV后1-7天全因住院IRR为0.9(95%CI 0.8-1.2,p=0.60)。
  • 两组在1-7天(p=0.88)和8-14天(p=0.24)风险窗口内全因住院风险无差异。

核心结论

  • 研究未发现与非哮喘非免疫受损基础病儿童相比,健康儿童接种LAIV后住院风险存在差异的证据。

研究设计与样本

  • 分析2010至2012年MarketScan商业索赔数据库,纳入2-18岁LAIV接种者。
  • 通过前一日历年内住院或门诊ICD-9编码定义基础病,排除哮喘和免疫受损情况。
  • 采用自控病例系列分析,条件泊松回归模型估计发生率比(IRR)。
  • 风险窗口为接种后1-7天和8-14天,对照期为接种前12-4天和接种后15-23天。

主要发现

  • 2010至2012年共有1,216,123名2-18岁儿童接种LAIV。
  • 634名儿童符合纳入标准并在观察期(接种前12天至接种后23天)内住院,其中72名(11.4%)有非哮喘非免疫受损基础病。
  • 有基础病儿童1-7天风险期全因住院IRR为1.1(95%CI 0.6-2.0,p=0.83),8-14天风险期IRR为0.9(95%CI 0.4-1.7,p=0.67)。
  • 无基础病儿童1-7天风险期全因住院IRR为0.9(95%CI 0.8-1.2,p=0.60),8-14天风险期IRR为1.1(95%CI 0.9-1.3,p=0.53)。
  • 有基础病与无基础病儿童在1-7天(p=0.88)和8-14天(p=0.24)风险期全因住院风险无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Live attenuated influenza vaccine (LAIV) is safe in healthy children ⩾2years. The original clinical trials excluded individuals with underlying conditions; however, post-marketing data suggest LAIV may be safe for these populations. METHODS: We analyzed MarketScan Commercial Claims Databases from 2010 to 2012 to describe hospitalizations within 14days of vaccination among LAIV recipients. We evaluated LAIV recipients aged 2-18years and defined underlying conditions by presence of inpatient or outpatient ICD-9 code during the previous calendar year. We excluded asthma and immunocompromising conditions. We defined risk windows as 1-7days and 8-14days after vaccination; the control period was 12-4days prior to and 15-23days after vaccination. We conducted a self-controlled case series analysis using a conditional Poisson regression model to estimate incidence-rate ratios (IRR). RESULTS: 1,216,123 children aged 2-18years received LAIV from 2010 to 2012. 634 children met our inclusion criteria and were hospitalized during the observation period (12days prior to vaccination to 23days after vaccination). Of those hospitalized, 72 (11.4%) had non-asthma, non-immunocompromising underlying conditions. Children with non-asthma, non-immunocompromising underlying conditions had an all-cause hospitalization IRR of 1.1 (95% CI 0.6-2.0, p=0.83) in the 1-7day risk period and 0.9 (95% CI 0.4-1.7, p=0.67) in the 8-14day risk period. Children with no underlying conditions had an all-cause hospitalization IRR of 0.9 (0.8-1.2, p=0.60) in the 1-7day risk period and 1.1 (95% CI 0.9-1.3, p=0.53) in the 8-14day risk period. There were no differences in all-cause hospitalization risk in individuals with non-asthma, non-immunocompromising underlying conditions compared to those without underlying conditions in the 1-7day (p=0.88) or 8-14day (p=0.24) risk period. CONCLUSIONS: We found no evidence of differences in post-LAIV hospitalization risk among children with non-asthma, non-immunocompromising underlying conditions compared to healthy children.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Millman AJ, Reynolds S, Duffy J, et al. Hospitalizations within 14days of vaccination among pediatric recipients of the live attenuated influenza vaccine, United States 2010-2012. Vaccine. 2016. PMID: 28041779. doi:10.1016/j.vaccine.2016.12.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。